APHARMAT
Board
1 director, no change since September 2026Director (not named in the articles), permanent representative
since 01-04-2020
term without a fixed end
listed in the 2025 annual accounts, filed on 15-07-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Each manager alonedeed of 23-12-2010
Permanent representatives 1
Mandates through the years
1 name, the dashed line is todayDirector (not named in the articles)
Board
Mandates as a list
-
- Director (not named in the articles), from 01-04-2020 to date
With Starter you also see 7 former office holders in the mandate history.
See the plans →
Control
Parent
Equity €748,258
Profit €34,519 in 2025 (profit €28,486 in 2024)
Checked score
Source: accounts 2025
100%
This company
APHARMAT
Equity €49,674
Profit €52,995 in 2025
Capital
- Contribution
- €6,200
- Shares
- 186
- Contribution per share
- €33.33
- Equity per share
- €267 in 2025
- Source
- 2025 annual accounts
Owners through the years
as the annual accounts name themOwners as a list
-
- 2020: consolidates
- 2021 to 2025: 100%
Source: parent in its own accounts, lists of holdings in the owners' accounts
Articles of association
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 09-07-2020 (in Dutch)
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- Voorafgaande bijzondere en geschreven toestemming van alle vennoten, nietigheiddeed of 23-12-2010 (in Dutch)
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Third Wednesday of June at 20:00deed of 23-12-2010 (in Dutch)
Capital transactions
Shareholders according to the deeds
At incorporation
deed of 23-12-2010 ↗
- founder
- founder
Capital over time
- 09-07-2020 Converted to unavailable equity
- 20-01-2016 Capital stated in the deed · €18,600 · 186 shares
- 23-12-2010 Incorporation · €18,600 · 186 shares